当前位置: 首页 > 详情页

Prevalence of right atrial non-pulmonary vein triggers in atrial fibrillation patients treated with thyroid hormone replacement therapy

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Inje Univ, Coll Med, Haeundae Paik Hosp, Dept Internal Med, Busan, South Korea; [2]St Davids Med Ctr, Texas Cardiac Arrhythmia Inst, 3000 N I-35,Suite 720, Austin, TX 78705 USA; [3]Dell Med Sch, Austin, TX 78712 USA; [4]Univ Penn, Philadelphia, PA 19104 USA; [5]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China; [6]Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA; [7]Montefiore Hosp, Albert Einstein Coll Med, Bronx, NY USA; [8]Univ Foggia, Dept Cardiol, Foggia, Italy; [9]Calif Pacific Med Ctr, San Francisco, CA 94114 USA
出处:
ISSN:

关键词: Atrial fibrillation Catheter ablation Thyroid hormone

摘要:
Thyroid hormone (TH) is known to enhance arrhythmogenicity, and high-normal thyroid function is related with an increased recurrence of atrial fibrillation (AF) after catheter ablation. However, the impact of thyroid hormone replacement (THR) on AF ablation is not well known. This study evaluated 1163 consecutive paroxysmal AF patients [160 (14%) on THR and 1003 (86%) without THR] undergoing their first catheter ablation. A total of 146 patients on THR and 146 controls were generated by propensity matching, based on calculated risk factor scores, using a logistic model (age, sex, body mass index, and left atrium size). The presence of non-pulmonary vein (PV) triggers was disclosed by a high-dose isoproterenol challenge (up to 30 mu g/min) after PV isolation. Clinical characteristics were not different between the groups. When compared to the control, non-PV triggers were significantly greater in the THR patients [112 (77%) vs. 47 (32%), P < 0.001], and most frequently originated from the right atrium (95 vs. 56%, P < 0.001). Other sources of non-PV triggers were the interatrial septum (25 vs. 11%, P = 0.002), coronary sinus (70 vs. 52%, P = 0.01), left atrial appendage (47 vs. 34%, P = 0.03), crista terminalis/superior vena cava (11 vs. 8%, P = 0.43), and mitral valve annulus (7 vs. 5%, P = 0.45) (THR vs. control), respectively. After mean follow-up of 14.7 +/- 5.2 months, success rate was lower in patients on THR therapy [94 (64.4%)] compared to patients not receiving THR therapy [110 (75.3%), log-rank test value = 0.04]. Right atrial non-PV triggers were more prevalent in AF patients treated with THR. Elimination of non-PV triggers provided better arrhythmia-free survival in the non-THR group.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统
JCR分区:
出版当年[2015]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
最新[2023]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Inje Univ, Coll Med, Haeundae Paik Hosp, Dept Internal Med, Busan, South Korea;
通讯作者:
通讯机构: [2]St Davids Med Ctr, Texas Cardiac Arrhythmia Inst, 3000 N I-35,Suite 720, Austin, TX 78705 USA; [3]Dell Med Sch, Austin, TX 78712 USA; [6]Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA; [9]Calif Pacific Med Ctr, San Francisco, CA 94114 USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院